Heritability, pQTLs, and environmental influence on proteins involved in age, cardiovascular risk, and glucose tolerance using the SomaScan® Assay
Background
- Cis-pQTLs: genetic variants correlated with levels of nearby proteins
- Cis-pQTLs are one piece of evidence of specificity for affinity-based proteomic assays; also useful for proteogenomic analyses, such as Mendelian randomization
- Protein levels reflect genetics, environment, and physiology, so not all proteins will have strong genetic
associations - Non-genetic influences captured by the proteome contribute to phenotypic variation
Methods
- Compiled a list of cis-pQTLs from 15 studies run on the SomaScan Assay [1-15], and extracted aptamer heritability from published results [14].
- Cross-tabulated cis-pQTL association and strong endpoint association (FDR < 10%): age, four-year cardiovascular disease risk (CVD), and oral glucose tolerance tests [16-17].
SomaScan® Assay Technology
- Measures 11,000 proteins using modified aptamers
- 10-log dynamic range
- Standardization method that enables easy cross-study data integration
- 21 SomaSignal® tests for non-invasive risk assessment and physiological measurements
- Ecosystem of publications and data analysis tools
Conclusions
- Endpoint-associated analytes are more likely to have a cis-pQTL or have non-zero heritability than non-endpoint-associated analytes
- Most analytes are sensitive to environmental effects
- Many endpoint-associated analytes do not have evidence of genetic influence
- Heritability levels are generally modest
- The variation in protein levels detected by the SomaScan Assay is reflective of both genetic variation and of non-genetic variation
Authors
Brendan Epstein
Ted Johnson
Tina Lai
Michael A. Hinterberg
David P. Astling
SomaLogic Operating Co., Inc., Boulder, CO USA
Click below for a downloadable version of this poster
More posters
PosterOptimizing biomarker discovery with focus on low coefficient of variation in large-scale proteomics
Coefficients of variation (CV) describe innate technical variation in high throughput molecular measurement platforms and are a standard metric for characterizing and monitoring assay precision. Median CVs range from ~4.5% to 18.0% for immunoassay technology, 1 up to >30% for mass spectrometry,2 ~5% for the SomaScan® Assay, and ~10% for the Olink Explore Assay (Figure 1). Large CVs can cause technical variability to overwhelm biological signal.
PosterA proteomic predictor of conversion from mild cognitive impairment to dementia with potential utility in enhancing productivity of emerging clinical trials
A significant proportion of individuals with mild cognitive impairment (MCI) develop dementia, with annual conversion rates exceeding 10%. Earlier dementia diagnosis and intervention can improve outcomes, and new disease-modifying drugs are being repositioned for the preclinical stages of illness.
PosterQuantitative immunology protein panel built on the SomaScan Assay platform
The SomaScan® assay is a highly multiplexed proteomic assay that uses SOMAmer® reagents to detect proteins in various biological samples. The latest version of the SomaScan assay allows researchers to measure over 11,000 proteins in human blood. The SomaScan assay is designed to provide protein epitope abundance measurements by reporting relative SOMAmer reagent abundance quantified using DNA microarrays.